Coronavirus update: Germany refreshes record daily infections, bad news from Remdesivir, Johnson and Johnson
|The latest coronavirus (COVID-19) updates from Germany’s Robert Koch Institute (RKI) suggest that the European powerhouse is in deep trouble as far as the virus is concerned.
The daily new cases rose past Thursday’s record level of 6,638 with 7,334 extra infections leading to 348,557 total counts. The death toll, however, seems to ease from the previous day’s 33 to 24 while marking a total of 9,734 fatalities.
Elsewhere, the World Health Organization (WHO) came out with the news that the previously cheered vaccine from Gilead Sciences Inc., Remdesivir, had little or no effect on COVID-19 patients' length of hospital stay or chances of survival.
Furthermore, Johnson and Johnson also updated its status over the vaccine trial halt by saying, it would take at least a few days for an independent safety panel to evaluate an unexplained illness of a study participant that led to a pause in the company’s COVID-19 vaccine trial,” as per Reuters.
Risks dwindle and so does EUR/USD…
The risk-negative news weighs on S&P 500 Futures as it currently marks 0.15% intraday losses to 3,472 versus the early-Asia’s mild risk-on mood. The US dollar index (DXY) remains on the positive front and hence pressures EUR/USD around 1.1700.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.